Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication

The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physicianâs discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how cons...

Full description

Bibliographic Details
Main Author: Philip Gentry, Anne Elissa
Other Authors: Dr. Melinda J. Beeuwkes Buntin
Format: Others
Language:en
Published: VANDERBILT 2016
Subjects:
Online Access:http://etd.library.vanderbilt.edu/available/etd-04042016-131002/
id ndltd-VANDERBILT-oai-VANDERBILTETD-etd-04042016-131002
record_format oai_dc
spelling ndltd-VANDERBILT-oai-VANDERBILTETD-etd-04042016-1310022016-04-12T05:28:33Z Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication Philip Gentry, Anne Elissa Law and Economics The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physicianâs discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how consumers respond to ambiguity in pharmaceutical risk. I also examine two areas where risk is either not directly regulated or is perceived to be insufficiently regulatedâI study whether patients, physicians, and third-party payers are sensitive to these risks or whether further regulation would be preferable. This dissertation begins by using an incentivized experiment to empirically estimate participantsâ reactions to ambiguity in risks that a drug is unsafe or ineffective in the presence of framing effects. The experiment finds that attitudes toward ambiguity are sensitive to risk type and framing effects. The dissertation then concentrates on two areas where risk is not directly regulated: The second chapter studies narrow therapeutic index drugs, drugs for which the generic approval process has been suspected to be inadequate in ensuring therapeutic equivalence. It finds evidence of a price penalty for the extra risk associated with NTI drugs. The third chapter studies off-label usesâthe prescription of a drug for an unapproved useâand examines whether inappropriate off-label uses are relinquished even in the absence of direct FDA regulation. It finds evidence that relinquishment of off-label uses can be spurred by False Claims Act suits. The dissertation provides insight into areas in which parties seem sensitive to risk absent regulation and those in which further regulation may be necessary. Dr. Melinda J. Beeuwkes Buntin Dr. W. Kip Viscusi James Blumstein Dr. Daniel Gervais VANDERBILT 2016-04-11 text application/pdf http://etd.library.vanderbilt.edu/available/etd-04042016-131002/ http://etd.library.vanderbilt.edu/available/etd-04042016-131002/ en unrestricted I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to Vanderbilt University or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report.
collection NDLTD
language en
format Others
sources NDLTD
topic Law and Economics
spellingShingle Law and Economics
Philip Gentry, Anne Elissa
Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
description The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physicianâs discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how consumers respond to ambiguity in pharmaceutical risk. I also examine two areas where risk is either not directly regulated or is perceived to be insufficiently regulatedâI study whether patients, physicians, and third-party payers are sensitive to these risks or whether further regulation would be preferable. This dissertation begins by using an incentivized experiment to empirically estimate participantsâ reactions to ambiguity in risks that a drug is unsafe or ineffective in the presence of framing effects. The experiment finds that attitudes toward ambiguity are sensitive to risk type and framing effects. The dissertation then concentrates on two areas where risk is not directly regulated: The second chapter studies narrow therapeutic index drugs, drugs for which the generic approval process has been suspected to be inadequate in ensuring therapeutic equivalence. It finds evidence of a price penalty for the extra risk associated with NTI drugs. The third chapter studies off-label usesâthe prescription of a drug for an unapproved useâand examines whether inappropriate off-label uses are relinquished even in the absence of direct FDA regulation. It finds evidence that relinquishment of off-label uses can be spurred by False Claims Act suits. The dissertation provides insight into areas in which parties seem sensitive to risk absent regulation and those in which further regulation may be necessary.
author2 Dr. Melinda J. Beeuwkes Buntin
author_facet Dr. Melinda J. Beeuwkes Buntin
Philip Gentry, Anne Elissa
author Philip Gentry, Anne Elissa
author_sort Philip Gentry, Anne Elissa
title Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
title_short Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
title_full Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
title_fullStr Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
title_full_unstemmed Safety and Effectiveness: The FDAâs Approach to Risk in Prescription Medication
title_sort safety and effectiveness: the fdaâs approach to risk in prescription medication
publisher VANDERBILT
publishDate 2016
url http://etd.library.vanderbilt.edu/available/etd-04042016-131002/
work_keys_str_mv AT philipgentryanneelissa safetyandeffectivenessthefdaasapproachtoriskinprescriptionmedication
_version_ 1718222087052591104